The Venture Collective

What The Venture Collective does

The Venture Collective (TVC) is a privately-held, early-stage venture capital firm founded in 2019 and headquartered in New York. The firm invests seed through Series B capital in companies building transformative technology and science aimed at three stated verticals: human health and longevity (data-powered care delivery, novel modalities, AI-driven drug discovery, underserved CPG), planetary sustainability (agtech, sustainable materials and chemicals, advanced computing, aerospace and defense), and inclusive digital infrastructure (consumer/SMB enablement, vertically applied AI). TVC positions itself as founder-aligned and milestone-driven, deploying capital early with conviction and providing personalized operational support intended to help portfolio companies traverse the "Valley of Death" between inception and product-market fit.

TVC's underlying platform is not a software product but an investment and advisory platform composed of its partners, senior advisors, and a global Venture Partners network. The firm draws differentiation from the operating credentials of its team — Founding Partners Nicholas Shekerdemian (Thiel Fellow, YC alumnus, 60+ angel investments) and Gina Shekerdemian (former BlackRock Director, Forbes 30 Under 30), plus partners and advisors with backgrounds at OpenAI, Walmart eCommerce, Jet.com, AstraZeneca, Moelis, Merrill Lynch, BlackRock, and Imperial College London — and from its brand positioning around impact-driven venture investing tied to the "Great Wealth Transfer" thesis. Revenue is generated from venture capital economics (management fees and carried interest on fund returns) rather than product sales; the firm does not publicly disclose AUM, fund size, or revenue.

TVC's go-to-market is relationship-driven: direct sourcing through founder networks, warm introductions from its Venture Partner base, and co-investment with other institutional investors (Merck Global Health Innovation Fund, General Catalyst, SOSV, Argenx). Its portfolio spans 40+ companies including Axiom Space (unicorn), X-Energy (exit), Wonderbelly (acquired by P&G), Orbem, Unnatural Products, Qloo, Life Biosciences, Cocoon Carbon, Mach, and Lyric Bio, with active geographic exposure across the US, UK, Germany, France, India, Bangladesh, Singapore, and Canada. Recognized on Blueprint Capital Advisors' 2025 and 2026 Power100 Asset Managers lists and named 2023 Best Early Stage Venture Firm (Northeast USA) by Wealth & Finance.

Name

The Venture Collective

Legal name

The Venture Collective LLC

Website

https://www.theventurecollective.com/

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

The Venture Collective is a New York-based early-stage venture capital firm founded in 2019 that invests in transformative technology and science companies across healthcare, climate/industrial transformation, and digital infrastructure, providing capital, operational support, and milestone-based follow-on to portfolio founders globally.

Ownership category

akta.pro rank

Product category

Early-Stage Venture Capital

NAICS

Other Investment Pools and Funds (5259)

SIC

Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Early-stage venture capital
• Venture capital firm
• Startup seed funding
• Series A investments
• Impact venture investing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Venture Capital Returns: TVC generates returns through equity investments in early-stage startups. They invest their capital, time, and network into highly defensible, fast-growing companies with the potential to solve the world's biggest problems. Returns come from portfolio company exits, IPOs, and secondary sales.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

The Venture Collective is an early-stage venture capital firm that deploys capital, operational support, and a network of world-class entrepreneurs and business leaders into highly defensible, fast-growing companies solving the world's biggest problems. It focuses on healthcare, climate/industrial transformation, and digital infrastructure, investing with conviction, personalizing founder support through the Valley of Death, and doubling down based on milestones rather than time.

Product overview

The Venture Collective is an early-stage venture capital firm that provides investment capital, strategic support, and network access to founders building purpose-driven companies in healthcare, climate/industrial transformation, and digital infrastructure. The firm does not offer a distinct product platform but rather serves as an investment vehicle and operational partner to its portfolio companies, offering milestone-based follow-on funding and personalized support to help startups traverse the early-stage period known as the Valley of Death.

Differentiator

Problem solved

Functional benefit

Products and services

• Early-Stage Venture Capital Investment
• Founder Operational Support Program

Quantifiable outcome

• The Great Wealth Transfer will generate $75T in capital for Millennials and Gen Z who are 2X as likely to focus on altruistic investing

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Merck Digital Sciences Studio (MDSS)coreStrategic or Co-development Partner · 13 March 2026TVC participates as a consortium partner in the Merck Digital Sciences Studio accelerator based in Montreal, Canada. The nine-month accelerator supports 12 biopharmaceutical startups focused on digital technologies including AI solutions. Each selected startup receives $100,000 USD in funding from the consortium including Merck Global Health Innovation Fund, The Venture Collective, and CQDM. TVC provides mentorship alongside Merck and operating partner Centech.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• SOSV: Multi-stage, multi-program deep-tech accelerator/VC (Hax, IndieBio, dlab) and repeat TVC co-investor in portfolio companies including Cocoon Carbon and Orbem. Significantly larger and broader in scope, but directly competitive in deep-tech seed and Series A rounds.
• Breakthrough Energy Ventures: Climate-focused, patient-capital early-stage fund backed by high-profile LPs, with deep overlap with TVC's climate/industrial transformation thesis (Cocoon Carbon, X-Energy). Operates at significantly larger scale.
• General Catalyst: Large multistage VC and repeat TVC co-investor in Orbem (€55.5M Series B). Operates across far more stages and geographies than TVC but overlaps in transformative-tech and healthcare bets.
• Khosla Ventures: Large, thesis-driven VC investing aggressively in transformative technology across climate, healthcare, and frontier tech. Overlaps with TVC's 'world's biggest problems' thesis at far greater scale and check size.

Direct peers

• Primary Ventures: Early-stage venture firm where TVC General Partner Cat Middleton was previously a Partner. Both invest in early-stage founders across consumer and enterprise with a hands-on operating model, making it a direct comparable for TVC's people-driven approach.
• Lux Capital: Early-stage VC backing founders in science and tech-driven ventures (aerospace, biology, energy, AI), with comparable focus areas to TVC's aerospace, biotech, and industrial bets. Similar founder-led, conviction-driven approach.
• 2150: Early-stage VC focused on technology reshaping the urban environment and industrial sectors, and lead investor in Cocoon Carbon's $15M Series A alongside TVC. Closely comparable thesis around transformative industrial/climate tech at seed/Series A.
• BlueYard Capital: Early-stage deep-tech VC investing in founders at the intersection of decentralized compute, biology, and frontier science, where TVC Associate Ines Ullmo previously served as a Venture Fellow. Highly comparable thesis and fund size to TVC.
• Alix Ventures: Bio-focused venture firm where TVC Principal Chris Ghadban previously worked as Principal. Both are smaller, science-led early-stage VCs backing technical founders in biotech and bio-adjacent categories.

Regional players

• Innovation Industries: European deep-tech VC that led Orbem's €55.5M Series B alongside TVC. Comparable in deep-tech/industrial focus but primarily serves European founders and LPs, making it a regional rather than direct US competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/hellotvc
• LinkedInlinkedin.com/company/the-venture-collective

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments79 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Venture Collective